Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma-Reference-Cited by-同舟云学术

Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma

Published:2016-10-06 Issue:14 Volume:128 Page:1814-1820
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Albertsson-Lindblad Alexandra¹,Kolstad Arne²^ORCID,Laurell Anna³,Räty Riikka⁴,Grønbæk Kirsten⁵,Sundberg Jan¹,Pedersen Lone Bredo⁵,Ralfkiær Elisabeth⁶,Karjalainen-Lindsberg Marja-Liisa⁷,Sundström Christer⁸^ORCID,Ehinger Mats⁹^ORCID,Geisler Christian⁵,Jerkeman Mats¹^ORCID

Affiliation:

1. Department of Oncology, Skåne University Hospital, Lund, Sweden;

2. Department of Oncology, Oslo University Hospital, Oslo, Norway;

3. Department of Oncology, Uppsala University Hospital, Uppsala, Sweden;

4. Department of Hematology, Helsinki University Hospital, Helsinki, Finland;

5. Department of Hematology, Rigshospitalet, Copenhagen, Denmark;

6. Department of Pathology, Rigshospitalet, Copenhagen, Denmark;

7. Department of Pathology, Helsinki University Central Hospital, Helsinki, Finland;

8. Department of Pathology, Uppsala University Hospital, Uppsala, Sweden; and

9. Department of Pathology/Cytology, Lund University Hospital, Lund, Sweden

Abstract

Key PointsAddition of lenalidomide to R-B is highly active in patients with untreated MCL, but associated with unexpected high rates of infections and SPMs.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/128/14/1814/1396178/1814.pdf

Reference35 articles.

1. Improvement of overall survival in advanced stage mantle cell lymphoma.;Herrmann;J Clin Oncol,2009

2. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.;Hoster;Blood,2008

3. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.;Hoster;J Clin Oncol,2014

4. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).;Geisler;Blood,2010

5. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.;Budde;J Clin Oncol,2011

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. More is not always better;Blood;2024-09-05

2. Minimal Residual Disease Testing for Classical Hodgkin Lymphoma: A Comprehensive Review;Critical Reviews in Oncology/Hematology;2024-09

3. Answering the “Doctor, can CAR-T therapy cause cancer?” question in clinic;Blood Advances;2024-02-15

4. Epidemiological, clinical and therapeutic profiles of mantle cell lymphoma cared for in a Moroccan center: a review of 14 cases;The Pan African Medical Journal;2024

5. Recent advances in genomics and therapeutics in mantle cell lymphoma;Cancer Treatment Reviews;2024-01